The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs
Abstract
Osteosarcoma (OS) is the most common primary malignancy of the bone and has a high propensity for local invasion and metastasis. Although combining surgery with chemotherapy has immensely improved the outcomes of osteosarcoma patients, the prognosis of metastatic or recurrent osteosarcomas is still unsatisfactory. Immunotherapy has proven to be a promising therapeutic strategy against human malignancies and improved understanding of the immune response to OS, and biomarker development has increased the number of patients who benefit from immunotherapies in recent years. Here, we review recent advances in immunotherapy in osteosarcoma and discuss the mechanisms and status of immunotherapies in both preclinical and clinical trials as well as future therapies on the horizon. These advances may pave the way for novel treatments requisite for patients with osteosarcoma in need of new therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,632
Gust, J., Hay, K. A., Hanafi, L.-A., Li, D., Myerson, D., Gonzalez-Cuyar, L. F., Yeung, C., Liles, W. C., Wurfel, M., Lopez, J. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0698 · Cited by 1,400
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis
Shibuya, M., & Claesson-Welsh, L. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.012 · Cited by 1,062
Parkhurst, M. R., Yang, J. C., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,020
Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
Long, G. V., Dummer, R., Hamid, O., Gajewski, T. F., Caglevic, C., Dalle, S., Arance, A., Carlino, M. S., Grob, J.-J., Kim, T. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30274-8 · Cited by 960
D'Angelo, S. P., Mahoney, M. R., Van Tine, B. A., Atkins, J., Milhem, M. M., Jahagirdar, B. N., Antonescu, C. R., Horvath, E., Tap, W. D., Schwartz, G. K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30006-8 · Cited by 759
Current and future therapeutic approaches for osteosarcoma
Harrison, D. J., Geller, D. S., Gill, J. D., Lewis, V. O., & Gorlick, R. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1413939 · Cited by 689
Majzner, R. G., Theruvath, J. L., Nellan, A., Heitzeneder, S., Cui, Y., Mount, C. W., Rietberg, S. P., Linde, M. H., Xu, P., Rota, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0432 · Cited by 681
Exosomes and their roles in immune regulation and cancer
Greening, D. W., Gopal, S. K., Xu, R., Simpson, R. J., & Chen, W. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.02.009 · Cited by 597
Rodig, S. J., Gusenleitner, D., Jackson, D. G., Gjini, E., Giobbie-Hurder, A., Jin, C., Chang, H., Lovitch, S. B., Horak, C., Weber, J. S., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar3342 · Cited by 579
Buddingh, E. P., Kuijjer, M. L., Duim, R. A. J., Bürger, H., Agelopoulos, K., Myklebost, O., Serra, M., Mertens, F., Hogendoorn, P. C. W., Lankester, A. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2047 · Cited by 508
Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor
Ma, L., Dichwalkar, T., Chang, J. Y. H., Cossette, B., Garafola, D., Zhang, A. Q., Fichter, M., Wang, C., Liang, S., Silva, M., et al. (2019) · Science · doi:10.1126/science.aav8692 · Cited by 439
Mitchell, T. C., Hamid, O., Smith, D. C., Bauer, T. M., Wasser, J. S., Olszanski, A. J., Luke, J. J., Balmanoukian, A. S., Schmidt, E. V., Zhao, Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9602 · Cited by 388
Cancer associated fibroblasts: An essential role in the tumor microenvironment
Tao, L., Huang, G., Song, H., Chen, Y., & Chen, L. (2017) · Oncology Letters · doi:10.3892/ol.2017.6497 · Cited by 351
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
Merchant, M. S., Wright, M., Baird, K., Wexler, L. H., Rodriguez-Galindo, C., Bernstein, D., Delbrook, C., Lodish, M., Bishop, R., Wolchok, J. D., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0491 · Cited by 331
Lee, Y.-H., Martin-Orozco, N., Zheng, P., Li, J., Zhang, P., Tan, H., Park, H. J., Jeong, M., Chang, S. H., Kim, B.-S., et al. (2017) · Cell Research · doi:10.1038/cr.2017.90 · Cited by 328
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction
Contardi, E., Palmisano, G. L., Tazzari, P. L., Martelli, A. M., Falà, F., Fabbi, M., Kato, T., Lucarelli, E., Donati, D., Polito, L., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21155 · Cited by 324
Cancer stem cells in osteosarcoma
Brown, H. K., Tellez-Gabriel, M., & Heymann, D. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.11.019 · Cited by 303
Lundholm, M., Schröder, M., Nagaeva, O., Baranov, V., Widmark, A., Mincheva-Nilsson, L., & Wikström, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108925 · Cited by 291
Koirala, P., Roth, M. E., Gill, J., Piperdi, S., Chinai, J. M., Geller, D. S., Hoang, B. H., Park, A., Fremed, M. A., Zang, X., et al. (2016) · Scientific Reports · doi:10.1038/srep30093 · Cited by 267
Krupka, C., Kufer, P., Kischel, R., Zugmaier, G., Lichtenegger, F. S., Köhnke, T., Vick, B., Jeremias, I., Metzeler, K. H., Altmann, T., et al. (2016) · Leukemia · doi:10.1038/leu.2015.214 · Cited by 253
An investigation of the familial aspects of carcinoma of the prostate
Woolf, C. M. (1960) · Cancer · doi:10.1002/1097-0142(196007/08)13:4<739::aid-cncr2820130414>3.0.co;2-e · Cited by 242
CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2014.00385 · Cited by 224
Bone microenvironment signals in osteosarcoma development
Alfranca, A., Martinez-Cruzado, L., Tornin, J., Abarrategi, A., Amaral, T., de Alava, E., Menendez, P., Garcia-Castro, J., & Rodriguez, R. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1918-y · Cited by 223
Ahmed, N., Salsman, V. S., Yvon, E., Louis, C. U., Perlaky, L., Wels, W. S., Dishop, M. K., Kleinerman, E. E., Pule, M., Rooney, C. M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.133 · Cited by 215
Lussier, D. M., Johnson, J. L., Hingorani, P., & Blattman, J. N. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0067-z · Cited by 206
Ségaliny, A. I., Mohamadi, A., Dizier, B., Lokajczyk, A., Brion, R., Lanel, R., Amiaud, J., Charrier, C., Boisson‐Vidal, C., & Heymann, D. (2015) · International Journal of Cancer · doi:10.1002/ijc.29376 · Cited by 199
Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions
Lussier, D. M., O’Neill, L., Nieves, L. M., McAfee, M. S., Holechek, S. A., Collins, A. W., Dickman, P., Jacobsen, J., Hingorani, P., & Blattman, J. N. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000065 · Cited by 197
Han, Y., Guo, W., Ren, T., Huang, Y., Wang, S., Liu, K., Zheng, B., Yang, K., Zhang, H., & Liang, X. (2019) · Cancer Letters · doi:10.1016/j.canlet.2018.10.011 · Cited by 194
Self-citationProgrammed Cell Death Ligand 1 Expression in Osteosarcoma
Shen, J. K., Cote, G. M., Choy, E., Yang, P., Harmon, D., Schwab, J., Nielsen, G. P., Chebib, I., Ferrone, S., Wang, X., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0224 · Cited by 193
T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell Killing
Kudo, K., Imai, C., Lorenzini, P., Kamiya, T., Kono, K., Davidoff, A. M., Chng, W. J., & Campana, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1365 · Cited by 191
Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research
Wang, Z., & Cao, Y. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00176 · Cited by 184
Dhupkar, P., Gordon, N., Stewart, J., & Kleinerman, E. S. (2018) · Cancer Medicine · doi:10.1002/cam4.1518 · Cited by 183
Mason, N. J., Gnanandarajah, J. S., Engiles, J. B., Gray, F., Laughlin, D., Gaurnier-Hausser, A., Wallecha, A., Huebner, M., & Paterson, Y. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0088 · Cited by 178
Wang, L., Zhang, Q., Chen, W., Shan, B., Ding, Y., Zhang, G., Cao, N., Liu, L., & Zhang, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070689 · Cited by 177
Krishnadas, D. K., Shusterman, S., Bai, F., Diller, L., Sullivan, J. E., Cheerva, A. C., George, R. E., & Lucas, K. G. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-015-1731-3 · Cited by 176
Yin, Y., Boesteanu, A. C., Binder, Z. A., Xu, C., Reid, R. A., Rodriguez, J. L., Cook, D. R., Thokala, R., Blouch, K., McGettigan-Croce, B., et al. (2018) · Molecular Therapy - Oncolytics · doi:10.1016/j.omto.2018.08.002 · Cited by 176
Immunotherapy for osteosarcoma: Where do we go from here?
Wedekind, M. F., Wagner, L. M., & Cripe, T. P. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27227 · Cited by 172
Zhou, Q., Xian, M., Xiang, S., Xiang, D., Shao, X., Wang, J., Cao, J., Yang, X., Yang, B., Ying, M., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0259 · Cited by 168
Advances in immune checkpoint inhibitors for bone sarcoma therapy
Thanindratarn, P., Dean, D. C., Nelson, S. D., Hornicek, F. J., & Duan, Z. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2019.100221 · Cited by 165
A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric Sarcomas
Mackall, C. L., Rhee, E. H., Read, E. J., Khuu, H. M., Leitman, S. F., Bernstein, D., Tesso, M., Long, L. M., Grindler, D., Merino, M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4065 · Cited by 158
TGF-β Signaling in Bone Remodeling and Osteosarcoma Progression
Lamora, A., Talbot, J., Mullard, M., Royer, B. B.-L., Rédiní, F., & Verrecchia, F. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5110096 · Cited by 156
Zheng, B., Ren, T., Huang, Y., Sun, K., Wang, S., Bao, X., Liu, K., & Guo, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0560-1 · Cited by 151
Self-citationYu, W., Wang, Y., Zhu, J., Jin, L., Liu, B., Xia, K., Wang, J., Gao, J., Liang, C., & Tao, H. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.11.019 · Cited by 140
Wolf-Dennen, K., Gordon, N. B., & Kleinerman, E. S. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1747677 · Cited by 134
Kushner, B. H., Cheung, I. Y., Modak, S. I., Basu, E. M., Roberts, S. S., & Cheung, N. V. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4005 · Cited by 132
Huang, G., Yu, L., Cooper, L. J. N., Hollomon, M., Huls, H., & Kleinerman, E. S. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2778 · Cited by 127
Fu, J. L., Malm, I., Kadayakkara, D. K. K., Levitsky, H., Pardoll, D. M., & Kim, Y. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2685 · Cited by 127
Chapuis, A. G., Roberts, I. M., Thompson, J. A., Margolin, K. A., Bhatia, S., Lee, S. M., Sloan, H. L., Lai, I. P., Farrar, E. A., Wagener, F. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5142 · Cited by 127
Current and Emerging Targets in Immunotherapy for Osteosarcoma
Miwa, S., Shirai, T., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2019) · Journal of Oncology · doi:10.1155/2019/7035045 · Cited by 125
Current Status and Perspectives Regarding the Treatment of Osteosarcoma: Chemotherapy
Sakamoto, A., & Iwamoto, Y. (2008) · Reviews on Recent Clinical Trials · doi:10.2174/157488708785700267 · Cited by 117
Rainusso, N., Brawley, V. S., Ghazi, A., Hicks, M. J., Gottschalk, S., Rosen, J. M., & Ahmed, N. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2011.83 · Cited by 114
Zhou, Y., Slone, N., Chrisikos, T. T., Kyrysyuk, O., Babcock, R. L., Medik, Y. B., Li, H. S., Kleinerman, E. S., & Watowich, S. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000474 · Cited by 112
IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas
Huang, X., Park, H., Greene, J., Pao, J., Mulvey, E., Zhou, S. X., Albert, C. M., Moy, F., Sachdev, D., Yee, D., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0133152 · Cited by 109
Li, B., Wang, Z., Wu, H., Xue, M., Lin, P., Wang, S., Lin, N., Huang, X., Pan, W., Liu, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3801 · Cited by 109
Nanoparticle enhanced MRI can monitor macrophage response to CD47 mAb immunotherapy in osteosarcoma
Mohanty, S., Yerneni, K., Theruvath, J. L., Graef, C. M., Nejadnik, H., Lenkov, O. D., Pisani, L. J., Rosenberg, J., Mitra, S. S., Sweet-Cordero, A., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-018-1285-3 · Cited by 109
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Yoshida, K., Okamoto, M., Sasaki, J., Kuroda, C., Ishida, H., Ueda, K., Ideta, H., Kamanaka, T., Sobajima, A., Takizawa, T., et al. (2020) · BMC Cancer · doi:10.1186/s12885-019-6499-y · Cited by 108
Jiang, K., Li, J., Zhang, J., Wang, L., Zhang, Q., Ge, J., Guo, Y., Wang, B., Huang, Y., Yang, T., et al. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105818 · Cited by 107
Self-citationExosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients
Wang, J., Zhang, H., Sun, X., Wang, X., Ren, T., Huang, Y., Zhang, R., Zheng, B., & Guo, W. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00710-6 · Cited by 97
Self-citationPaucity of dendritic cells in pancreatic cancer
Dallal, R. M., Christakos, P., Lee, K., Egawa, S., Son, Y., & Lotze, M. T. (2002) · Surgery · doi:10.1067/msy.2002.119937 · Cited by 95
He, X., Lin, H., Li, Y., & Li, B. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1276136 · Cited by 92
Emerging trends in immunotherapy for pediatric sarcomas
Dyson, K. A., Stover, B. D., Grippin, A., Méndez‐Gómez, H. R., Lagmay, J., Mitchell, D. A., & Sayour, E. J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0756-z · Cited by 91
Zheng, B., Ren, T., Huang, Y., & Guo, W. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.12.032 · Cited by 89
CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models
Xu, J.-F., Pan, X.-H., Zhang, S.-J., Zhao, C., Qiu, B.-S., Gu, H.-F., Hong, J.-F., Cao, L., Chen, Y., Xia, B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4282 · Cited by 88
Self-citationGoing back to class I: MHC and immunotherapies for childhood cancer
Haworth, K. B., Leddon, J. L., Chen, C., Horwitz, E. M., Mackall, C. L., & Cripe, T. P. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25359 · Cited by 87
Self-citationRen, T., Zheng, B., Huang, Y., Wang, S., Bao, X., Liu, K., & Guo, W. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1497-1 · Cited by 83
Self-citationTroyer, R. M., Ruby, C. E., Goodall, C. P., Yang, L., Maier, C. S., Albarqi, H. A., Brady, J. V., Bathke, K., Taratula, O., Mourich, D. V., et al. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.07.011 · Cited by 81
Théoleyre, S., Mori, K., Cherrier, B., Passuti, N., Gouin, F., Rédiní, F., & Heymann, D. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-123 · Cited by 79
Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma
Wang, Y., Yu, W., Zhu, J., Wang, J., Xia, K., Liang, C., & Tao, H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1147-6 · Cited by 75
Sierro, S. R., Donda, A., Perret, R., Guillaume, P., Yagita∥, H., Lévy, F., & Romero, P. J. (2011) · European Journal of Immunology · doi:10.1002/eji.201041235 · Cited by 74
Tsukahara, T., Nabeta, Y., Kawaguchi, S., Ikeda, H., Sato, Y., Shimozawa, K., Ida, K., Asanuma, H., Hirohashi, Y., Torigoe, T., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0522 · Cited by 74
T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities
Wang, Z., Li, B., Ren, Y., & Ye, Z. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00353 · Cited by 73
Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma
Fultang, L., Gamble, L. D., Gneo, L., Berry, A. M., Egan, S. A., de Bie, F. J., Yogev, O., Eden, G. L., Booth, S., Brownhill, S. C., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-2139 · Cited by 73
Osteosarcoma: Current status of immunotherapy and future trends (Review)
Mori, K., Rédiní, F., Gouin, F., Cherrier, B., & Heymann, D. (2006) · Oncology Reports · doi:10.3892/or.15.3.693 · Cited by 69
Kawano, M., Tanaka, K., Itonaga, I., Iwasaki, T., Miyazaki, M., Ikeda, S., & Tsumura, H. (2016) · Oncology Letters · doi:10.3892/ol.2016.4175 · Cited by 69
Dong, J., Demarest, S. J., Sereno, A., Tamraz, S., Langley, E. J., Doern, A., Snipas, T., Perron, K., Joseph, I. B. J., Glaser, S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1018 · Cited by 68
Immunotherapy of Childhood Sarcomas
Roberts, S. S., Chou, A. J., & Cheung, N. V. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00181 · Cited by 66
Hingorani, P., Maas, M. L., Gustafson, M. P., Dickman, P. S., Adams, R. H., Watanabe, M., Eshun, F., Williams, J., Seidel, M. J., & Dietz, A. B. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0082-0 · Cited by 64
Larrain, M. T. I., Rabassa, M. E., Lacunza, E., Barbera, A., Cretón, A., Segal‐Eiras, A., & Croce, M. V. (2014) · Tumor Biology · doi:10.1007/s13277-014-1859-3 · Cited by 63
Li, B., Zhu, X., Sun, L., Li, Y., Zhang, J., Li, H., & Ye, Z. (2014) · Oncotarget · doi:10.18632/oncotarget.2505 · Cited by 62
Bone sarcomas in the immunotherapy era
Heymann, M., Schiavone, K., & Heymann, D. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14999 · Cited by 62
Immunotherapeutic Approaches to Sarcoma
Burgess, M. A., & Tawbi, H. A. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0345-5 · Cited by 61
(2001) · PubMed · Cited by 61
Li, Z., Xu, Q., Peng, H., Cheng, R.-L., Sun, Z., & Ye, Z. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.01.001 · Cited by 60
Wang, L., Kang, F., Sun, N., Wang, J., Chen, W., Li, D., & Shan, B. (2016) · Tumor Biology · doi:10.1007/s13277-016-5386-2 · Cited by 60
Terabe, M., Khanna, C., Bose, S., Melchionda, F., Mendoza, A., Mackall, C. L., Helman, L. J., & Berzofsky, J. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3421 · Cited by 57
Targeting the PD-1 pathway in pediatric solid tumors and brain tumors
Wagner, L. M., & Adams, V. R. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s124008 · Cited by 56
Chen, C., Zhang, L., Jiao, Y., Zhou, Y., Ge, Q., Li, P., Sun, X., & Lv, Z. (2019) · FEBS Letters · doi:10.1002/1873-3468.13387 · Cited by 56
Self-citationRivoltini, L., Arienti, F., Orazi, A., Cefalo, G., Gasparini, M., Gambacorti-Passerini, C. B., Fossati‐Bellani, F., & Parmiani, G. (1992) · Cancer Immunology Immunotherapy · doi:10.1007/bf01741792 · Cited by 54
Progress and Opportunities for Immune Therapeutics in Osteosarcoma
Lettieri, C. K., Appel, N., Labban, N., Lussier, D. M., Blattman, J. N., & Hingorani, P. (2016) · Immunotherapy · doi:10.2217/imt-2016-0048 · Cited by 54
Guan, Y., Zhang, R., Peng, Z., Dong, D., Wei, G., & Wang, Y. (2017) · Journal of bone oncology · doi:10.1016/j.jbo.2017.10.002 · Cited by 54
Anti-TGF-β Antibody Combined with Dendritic Cells Produce Antitumor Effects in Osteosarcoma
Kawano, M., Itonaga, I., Iwasaki, T., Tsuchiya, H., & Tsumura, H. (2012) · Clinical Orthopaedics & Related Research · doi:10.1007/s11999-012-2299-2 · Cited by 51
KAWANO, M., ITONAGA, I., IWASAKI, T., & TSUMURA, H. (2013) · Oncology Reports · doi:10.3892/or.2013.2224 · Cited by 51
Pritchard‐Jones, K., Spendlove, I., Wilton, C., Whelan, J., Weeden, S., Lewis, I., Hale, J. H., Douglas, C., Pagonis, C., Campbell, B. M., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602500 · Cited by 51
Guma, S. R., Lee, D. A., Yu, L., Gordon, N. B., Hughes, D. P. M., Stewart, J., Wang, W., & Kleinerman, E. S. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24801 · Cited by 50
Effect of the cytokine levels in serum on osteosarcoma
Xiao, H. P., Chen, L., Luo, G., Son, H., Prectoni, J. H., & Zheng, W. (2013) · Tumor Biology · doi:10.1007/s13277-013-1136-x · Cited by 49
Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies
Sun, C., Dotti, G., & Savoldo, B. (2016) · Blood · doi:10.1182/blood-2015-12-629089 · Cited by 48
Meazza, C., Cefalo, G., Massimino, M., Daolio, P. A., Pastorino, U., Scanagatta, P., Morosi, C., Podda, M. G., Ferrari, A., Terenziani, M., et al. (2017) · Medical Oncology · doi:10.1007/s12032-017-1052-9 · Cited by 47
Yahiro, K., Matsumoto, Y., Yamada, H., Endo, M., Setsu, N., Fujiwara, T., Nakagawa, M., Kimura, A., Shimada, E., Okada, S., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02508-9 · Cited by 47
Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma
Wang, J., Hu, C., Wang, J., Shen, Y., Bao, Q., He, F., Wang, H., Gong, L., Liu, Z., Hu, F., et al. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000281 · Cited by 46
Kiany, S., Huang, G., & Kleinerman, E. S. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1333214 · Cited by 43
PDGF/PDGFR effects in osteosarcoma and the “add-on” strategy
Xu, J. H., Xie, L., & Guo, W. (2018) · Clinical Sarcoma Research · doi:10.1186/s13569-018-0102-1 · Cited by 43
Self-citationTumour-Derived Extracellular Vesicles (EVs): A Dangerous “Message in A Bottle” for Bone
Cappariello, A., & Rucci, N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194805 · Cited by 41
Wang, Z., Wang, Z., Li, S., Li, B., Sun, L., Li, H., Lin, P., Wang, S., Teng, W., Zhou, X., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01239 · Cited by 40
The tetraspanin CD81 mediates the growth and metastases of human osteosarcoma
Mizoshiri, N., Shirai, T., Terauchi, R., Tsuchida, S., Mori, Y., Hayashi, D., Kishida, T., Arai, Y., Mazda, O., Nakanishi, T., et al. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00472-w · Cited by 40
Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma
KAWANO, M., TANAKA, K., ITONAGA, I., IWASAKI, T., MIYAZAKI, M., IKEDA, S., & TSUMURA, H. (2015) · Oncology Reports · doi:10.3892/or.2015.4161 · Cited by 38
Markel, J., Noore, J., Emery, E. J., Bobnar, H. J., Kleinerman, E. S., & Lindsey, B. A. (2018) · Sarcoma · doi:10.1155/2018/8694397 · Cited by 38
Liu, Z., Wen, J., Wu, C., Hu, C., Wang, J., Bao, Q., Wang, H., Wang, J., Zhou, Q., Li, W., et al. (2020) · Aging · doi:10.18632/aging.102679 · Cited by 37
Tsuda, N., Murayama, K., Ishida, H., Matsunaga, K., Komiya, S., Itoh, K., & Yamada, A. (2001) · Journal of Orthopaedic Research® · doi:10.1016/s0736-0266(00)90031-7 · Cited by 36
Butch, E. R., Mead, P. E., Diaz, V. A., Sheppard, H., Stewart, E. A., Mishra, J. K., Kim, J.-E., Bahrami, A., Dearling, J. L. J., Packard, A. B., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3340 · Cited by 34
Association of anti-HER2 antibody with graphene oxide for curative treatment of osteosarcoma
Li, L., Luo, C., Song, Z., Reyes‐Vargas, E., Clayton, F., Huang, J., Jensen, P. E., & Chen, X. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.11.001 · Cited by 33
Jeong, S.-N., & Yoo, S. Y. (2020) · Cancers · doi:10.3390/cancers12051070 · Cited by 33
TIPE1 suppresses osteosarcoma tumor growth by regulating macrophage infiltration
Chen, P., Zhou, J., Li, J., Zhang, Q., & Zuo, Q. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1927-z · Cited by 32
HER4 promotes cell survival and chemoresistance in osteosarcoma via interaction with NDRG1
Wang, H., Sun, W. Y., Sun, M., Fu, Z., Zhou, C., Wang, C., Zuo, D., Zhou, Z., Wang, G., Zhang, T., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.03.008 · Cited by 28
Self-citationUnusual abdominal metastases in osteosarcoma
Berhe, S., Danzer, E., Meyers, P. A., Behr, G. G., LaQuaglia, M. P., & Price, A. P. (2017) · Journal of Pediatric Surgery Case Reports · doi:10.1016/j.epsc.2017.09.022 · Cited by 26
He, J., Wang, J., Wang, D., Dai, S., Yv, T., Chen, P., Ma, R., Diao, C., & Lv, G. (2014) · Endocrine · doi:10.1007/s12020-013-0050-8 · Cited by 24
Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma
Zhang, J., Li, Y., Yang, S. Y. C., Zhang, L., & Wang, W. (2019) · Journal of bone oncology · doi:10.1016/j.jbo.2019.100245 · Cited by 23
Expression of B7-H3 in cancer tissue during osteosarcoma progression in nude mice
Yin, S. J., Wang, W., & Zhang, J. Y. (2015) · Genetics and Molecular Research · doi:10.4238/2015.november.13.9 · Cited by 20
Zhu, W., Mao, X., Wang, W., Chen, Y., Li, D., Li, H., & Dou, P. (2018) · Die Pharmazie · doi:10.31083/ph.2018.7836 · Cited by 17
(2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.1000-9604.2013.11.06 · Cited by 16
Yu, F.-B., & Miao, J. (2013) · Tumor Biology · doi:10.1007/s13277-013-0908-7 · Cited by 15
Nagamori, M., Kawaguchi, S., Murakami, M., Wada, T., Nagoya, S., Yamashita, T., Inobe, M., & Uede, T. (2002) · PubMed · Cited by 14
Yee, C., & Lizee, G. A. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000255 · Cited by 14
Dendritic Cell Immunotherapy is Effective for Lung Metastasis from Murine Osteosarcoma
Joyama, S., Naka, N., Tsukamoto, Y., Yoshikawa, H., & Itoh, K. (2006) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000229347.02834.5e · Cited by 12
Irradiation enhanced the effects of PD-1 blockade in brain metastatic osteosarcoma
Xia, L., Wu, H., & Qian, W. (2018) · Journal of bone oncology · doi:10.1016/j.jbo.2018.05.002 · Cited by 12
Kiany, S., & Gordon, N. B. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3684-7_24 · Cited by 10
Liu, S., Geng, P., Cai, X., & Wang, J. (2014) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2014.0023 · Cited by 8
Cited by
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Self-citationTu, J., Wang, D., Zheng, X., & Liu, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.911368 · Cited by 27
Dong, C., Wang, Z., Shen, P., Chen, Y., Wang, J., & Wang, H. (2022) · Bioengineered · doi:10.1080/21655979.2022.2051805 · Cited by 25
Li, F., Tang, H., Luo, X., Li, X., Luo, K., Liu, S., Liang, J., Liao, S., Zhong, C., Zhan, X., et al. (2023) · Cancer Science · doi:10.1111/cas.15821 · Cited by 22
Metadata
- Authors
- Chen, C., Xie, L., Ren, T., Huang, Y., Xu, J., & Guo, W.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 500
- Pages
- 1-10
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W3114999426
- Cited by
- 569
- References
- 141
- FWCI
- 27.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.